X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The net proceeds will be used for the development of TNT119 (budoprutug) designed for a broad range of autoimmune diseases, including systemic lupus erythematosus, immune thrombocytopenia.
Lead Product(s): Budoprutug
Therapeutic Area: Immunology Product Name: TNT119
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $120.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement June 27, 2024
Details:
Through the acquisition, the company will focus on the clinical development of TNT119 (budoprutug), designed for a broad range of autoimmune diseases including systemic lupus erythematosus.
Lead Product(s): Budoprutug
Therapeutic Area: Immunology Product Name: TNT119
Highest Development Status: Phase IProduct Type: Large molecule
Recipient: Tenet Medicines
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition June 27, 2024
Details:
The net proceeds will be used for the development of TNT119 (budoprutug), a best-in class anti-CD19 antibody, designed for a broad range of autoimmune diseases, including systemic lupus erythematosus, immune thrombocytopenia and membranous nephropathy.
Lead Product(s): Budoprutug
Therapeutic Area: Immunology Product Name: TNT119
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: RA Capital Management
Deal Size: $120.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement April 11, 2024
Details:
The combined company will focus on clinical development of lead product candidate, TNT119 (budoprutug), a best-in class anti-CD19 antibody, in upcoming Phase 2 clinical trials in systemic lupus erythematosus and immune thrombocytopenia.
Lead Product(s): Budoprutug
Therapeutic Area: Immunology Product Name: TNT119
Highest Development Status: Phase IProduct Type: Large molecule
Recipient: Tenet Medicines
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition April 11, 2024
Details:
ETX-155 is a novel GABAA receptor positive allosteric modulator (GABAA PAM) that is being developed for the treatment of major depressive disorder (MDD) and epilepsy.
Lead Product(s): ETX-155
Therapeutic Area: Psychiatry/Psychology Product Name: ETX-155
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 05, 2022
Details:
In Phase 2a trial in LSRP, ETX-810 (ETX-018810) did not achieve statistically significant separation from placebo on trial’s primary endpoint, which assessed change from baseline to week 4 in average of daily pain score measured with Pain Intensity Numerical Rating Scale.
Lead Product(s): ETX-018810
Therapeutic Area: Neurology Product Name: ETX-810
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 01, 2022
Details:
ETX-155 is an investigational oral, next generation, neuroactive steroid NCE that acts as a GABAA positive allosteric modulator (PAM) designed to address the shortcomings of other molecules targeting the GABAA channel.
Lead Product(s): ETX-155
Therapeutic Area: Psychiatry/Psychology Product Name: ETX-155
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 18, 2022
Details:
In Phase 2a clinical trial in DPNP, ETX-810 did not achieve statistically significant separation from placebo on trial’s primary endpoint, which assessed change from baseline to week 4 in weekly average of daily pain score measured with Pain Intensity Numerical Rating Scale.
Lead Product(s): ETX-810
Therapeutic Area: Neurology Product Name: ETX-810
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 25, 2022
Details:
ETX-810 and ETX-155, ETX-810 is a novel palmitoylethanolamide (PEA) prodrug initially being developed for the treatment of diabetic peripheral neuropathic pain (DPNP) and pain associated with lumbosacral radiculopathy (LSR, commonly referred to as sciatica).
Lead Product(s): ETX-810
Therapeutic Area: Neurology Product Name: ETX-018810
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Public Offering July 19, 2021
Details:
Eliem plans to use the proceeds to advance its two lead clinical-stage product candidates, ETX-810 and ETX-155, across four different indications in patients with chronic pain, depressive disorders, and epilepsy, as well as two preclinical-stage programs.
Lead Product(s): ETX-810
Therapeutic Area: Neurology Product Name: ETX-810
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Intermediate Capital Group
Deal Size: $60.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing May 24, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
